GO
Loading...

Enter multiple symbols separated by commas

Stocks Johnson & Johnson

More

  • For those aged 34 or younger, their No. 2 favorite stock- behind only mighty Apple Inc- is none other than Warren Buffett's Berkshire Hathaway Inc.. This is according to new data from the brokerage TD Ameritrade, which took a snapshot in May of the individual equity holdings of every one of its retail clients. Among the top picks for young adults aged 34 and younger:...

  • *Deal gives Cardinal Health more generic volume. June 5- Cardinal Health Inc said it would buy privately held drug distributor Harvard Drug Group for $1.12 billion to boost volumes of its generic distribution business. The Livonia, Michigan- based Harvard Drug Group, a distributor of generic and over-the-counter drugs, had revenue of about $450 million in 2014,...

  • June 5- Cardinal Health Inc said it would buy privately held drug distributor Harvard Drug Group for $1.12 billion to expand its customer base and bolster its generics business. The Harvard Drug Group is a distributor of generic and over-the-counter drugs. The Harvard Drug Group had revenues of about $450 million in 2014, Cardinal health said in a statement.

  • After BMY's drop, cancer drug stocks set to move? Monday, 1 Jun 2015 | 5:00 AM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.

  • Birinyi sees 6% gain from here Friday, 29 May 2015 | 2:05 PM ET
    Laszlo Birinyi, president of Birinyi Associates

    Legendary trader Laszlo Birinyi sees all the bearish talk from his peers and the media and takes the opposite view.

  • *First-quarter GDP revised down to show contraction. *GDP shrinks at a 0.7 percent annual rate. WASHINGTON, May 29- The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls, a resurgent dollar and disruptions at West Coast ports, but activity already has rebounded modestly.

  • This stock is no longer in the Top 20 most held Friday, 29 May 2015 | 11:51 AM ET
    Traders work on the floor of the New York Stock Exchange.

    New data provided to CNBC from eVestment shows the most popular stocks held by institutional funds.

  • US contracts in Q1; dollar hits corporate profits Friday, 29 May 2015 | 8:35 AM ET
    Electronics assembly

    The U.S. economy contracted in the first quarter as it buckled under the weight of heavy snowfalls and a resurgent dollar, but activity has rebounded.

  • *First-quarter GDP revised down to show contraction. *GDP shrinks at a 0.7 percent annual rate. WASHINGTON, May 29- The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls and a resurgent dollar, but activity has rebounded modestly.

  • NEW YORK, May 28- Visa Inc's public warning to FIFA that it may end its sponsorship if world soccer's governing body does not quickly clean up its act will likely prompt other sponsors to take a tough stance as a major corruption scandal involving FIFA unfolds, brand experts said. After U.S. prosecutors indicted nine FIFA officials and five sports media and...

  • May 28- A Delaware jury on Thursday ordered Boston Scientific to pay $100 million to a woman who said she was injured by transvaginal mesh, a device that is the subject of more than 25,000 lawsuits against the company. The 51- year old Newark, Delaware- resident was implanted with Boston Scientific's Pinnacle and Advantage Fit mesh products in 2009, to treat...

  • J&J accepts offer from Cardinal Health for Cordis Thursday, 28 May 2015 | 9:49 AM ET
    Johnson & Johnson

    Health care giant Johnson & Johnson has formally accepted a $1.94 billion offer to sell its Cordis heart devices unit to Cardinal Health.

  • May 27- The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson& Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported. A J&J spokesman said the company has not been contacted by the FBI regarding its Ethicon morcellation devices.

  • May 27- The Federal Bureau of Investigation is looking into what Johnson& Johnson knew about the risks posed by a surgical tool in spreading uterine cancer before withdrawing its version of the device last year, the Wall Street Journal reported. J&J said in July that it would ask doctors to return the device, called laparoscopic power morcellator, which is used to...

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks closed about 1 percent lower as investors eyed renewed strength in the dollar and data that could strengthen the case for a rate hike.

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • J&J can weather new biotech threat: Analyst Wednesday, 20 May 2015 | 4:33 PM ET
    Johnson & Johnson

    Cheaper biotech drugs are headed to the U.S., but analyst Mike Weinstein thinks J&J can manage through some of the challenges.

  • The hep C challenge Wednesday, 20 May 2015 | 3:37 PM ET
    The hep C challenge

    Analysts tend to leave out Johnson & Johnson's hepatitis C drug out of the company's growth projections. Details, with NBC's Meg Tirrell.

  • May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United...

  • 19)@ (Corrects paragraphs 2 and 3 to say J&J's $1.1 billion potential payments include equity investment of $225 million and are not in addition to the $1.1 billion). May 19 (Reuters)- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and...